ATE315936T1 - Medikamente zur verhinderung von eingriffsbedingter stenose als folge von nicht- bypass invasiver eingriffe - Google Patents

Medikamente zur verhinderung von eingriffsbedingter stenose als folge von nicht- bypass invasiver eingriffe

Info

Publication number
ATE315936T1
ATE315936T1 AT96921645T AT96921645T ATE315936T1 AT E315936 T1 ATE315936 T1 AT E315936T1 AT 96921645 T AT96921645 T AT 96921645T AT 96921645 T AT96921645 T AT 96921645T AT E315936 T1 ATE315936 T1 AT E315936T1
Authority
AT
Austria
Prior art keywords
stenosis
medications
result
invasive procedures
bypass
Prior art date
Application number
AT96921645T
Other languages
English (en)
Inventor
Anthony H Cincotta
Original Assignee
Pliva D D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva D D filed Critical Pliva D D
Application granted granted Critical
Publication of ATE315936T1 publication Critical patent/ATE315936T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Endoscopes (AREA)
AT96921645T 1995-05-31 1996-05-30 Medikamente zur verhinderung von eingriffsbedingter stenose als folge von nicht- bypass invasiver eingriffe ATE315936T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/455,354 US5565454A (en) 1995-05-31 1995-05-31 Method for preventing intervention-associated stenosis and other symptoms associated with stenosis of blood vessels following non-bypass, invasive interventions

Publications (1)

Publication Number Publication Date
ATE315936T1 true ATE315936T1 (de) 2006-02-15

Family

ID=23808460

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96921645T ATE315936T1 (de) 1995-05-31 1996-05-30 Medikamente zur verhinderung von eingriffsbedingter stenose als folge von nicht- bypass invasiver eingriffe

Country Status (9)

Country Link
US (2) US5565454A (de)
EP (2) EP1661571A3 (de)
JP (2) JP4480799B2 (de)
AT (1) ATE315936T1 (de)
CA (1) CA2219452A1 (de)
DE (1) DE69635754T9 (de)
DK (1) DK0828492T3 (de)
ES (1) ES2255080T3 (de)
WO (1) WO1996038148A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565454A (en) * 1995-05-31 1996-10-15 Ergo Science, Incorporated Method for preventing intervention-associated stenosis and other symptoms associated with stenosis of blood vessels following non-bypass, invasive interventions
US6376467B1 (en) * 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
US6844333B1 (en) * 1999-03-26 2005-01-18 The Trustees Of The University Of Pennsylvania Method of treating atherosclerosis
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
ES2763873T3 (es) 2007-06-21 2020-06-01 Veroscience Llc Método de tratamiento de trastornos metabólicos y depresión con agonistas del receptor de dopamina
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US8431155B1 (en) 2012-04-30 2013-04-30 Veroscience Llc Bromocriptine formulations
EP3445362B1 (de) 2016-04-20 2021-09-22 VeroScience LLC Zusammensetzung und verfahren zur behandlung von stoffwechselstörungen
WO2019079623A1 (en) 2017-10-18 2019-04-25 Veroscience Llc ENHANCED BROMOCRIPTINE FORMULATIONS
CA3149877A1 (en) 2019-09-23 2021-04-01 Anthony H. Cincotta Method for inducing tumor regression

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE890369A (fr) * 1980-09-18 1982-03-16 Sandoz Sa Nouveaux medicaments a base d'inhibiteurs de la secretion de la prolactine pour le traitement de l'arteriosclerose
US4783469A (en) * 1986-03-07 1988-11-08 Meier Albert H Method of inhibiting body fat stores
US4659715A (en) * 1986-03-07 1987-04-21 Louisiana State University And Agricultural And Mechanical College Method of inhibiting body fat stores
US4749709A (en) * 1986-03-07 1988-06-07 Louisiana State University And Agricultural And Mechanical College Method of inhibiting body fat stores
DE3728695A1 (de) * 1987-08-25 1989-03-09 Schering Ag Neue benzimidazol-derivate
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5006526A (en) * 1988-10-17 1991-04-09 Louisiana State University Method of treating a vertebrate animal to reduce plasma triglycerides and cholesterol levels and to alleviate and prevent atherosclerosis
CA2117075A1 (en) * 1991-09-06 1993-03-18 Norihiko Shimazaki Quinazoline derivatives and their preparation
DE4315349A1 (de) * 1992-10-06 1994-11-10 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5342348A (en) * 1992-12-04 1994-08-30 Kaplan Aaron V Method and device for treating and enlarging body lumens
US5565454A (en) * 1995-05-31 1996-10-15 Ergo Science, Incorporated Method for preventing intervention-associated stenosis and other symptoms associated with stenosis of blood vessels following non-bypass, invasive interventions

Also Published As

Publication number Publication date
DE69635754D1 (de) 2006-04-06
CA2219452A1 (en) 1996-12-05
EP1661571A3 (de) 2006-08-02
WO1996038148A1 (en) 1996-12-05
JPH11507334A (ja) 1999-06-29
US5565454A (en) 1996-10-15
EP0828492B1 (de) 2006-01-18
EP1661571A2 (de) 2006-05-31
MX9709163A (es) 1998-03-31
DK0828492T3 (da) 2006-03-06
EP0828492A1 (de) 1998-03-18
DE69635754T9 (de) 2007-03-08
ES2255080T3 (es) 2006-06-16
DE69635754T2 (de) 2006-07-27
JP4480799B2 (ja) 2010-06-16
EP0828492A4 (de) 1999-07-07
US5902811A (en) 1999-05-11
JP2007182447A (ja) 2007-07-19

Similar Documents

Publication Publication Date Title
ATE315936T1 (de) Medikamente zur verhinderung von eingriffsbedingter stenose als folge von nicht- bypass invasiver eingriffe
DE69332624D1 (de) WUNDHEILMITTEL UND BEHANDLUNG VON FIBROTISCHEN STORUNGEN DURCH TGFbeta-3
BR9507858A (pt) Aplicação de um composto inibidor de prolactina para preparar um medicamento para o tratamento de uma disfunção do sistema imunitário aplicação de um composto estimulador de prolactina para preparar um medicamento para o tratamento de uma disfunção do sistema imunitário aplicação de um composto estimulador de prolactina para preparar um medicamento para o tratamento de uma doença autoimunitária e pacote terapêutico
ATE264099T1 (de) Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen
DE69012591D1 (de) Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen.
DE3873800D1 (de) Zusammensetzungen zur behandlung von hypercholesterinaemie.
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
UA41906C2 (uk) Спосіб лікування неврологічних порушень, викликаних травмами
BG97678A (en) Beta -carotene and/or vitamin e therapy for inhibition of major vascular events
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
DE3480053D1 (en) A kit or device and method for administering gangliosides and derivatives thereof of inhalation and pharmaceutical compositions suitable therefor
KR100321319B1 (ko) 물질남용장애를치료하는방법및제약학적조성물
EP0429522A4 (en) Phosphosugar-based anti-inflammatory and/or immunosuppressive drugs
EP0286802A3 (de) Verwendung von Ofloxacin zur lokalen Behandlung oder Prophylaxe von Beschwerden der Wurzelhaut der Zähne
DE69434002D1 (de) 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis
SU1169655A1 (ru) Способ лечени тромбооблитерирующих заболеваний артерий конечностей
GB8818116D0 (en) Compounds & compositions for medical treatment
ATE207353T1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
NO961496L (no) Behandling av allergiske sykdommer med terfenadinkarboksylat
RU93048255A (ru) Способ лечения вибрационной болезни
DE69411833D1 (de) Verwendung von Chinonen zur Herstellung eines Arzneimittels zur Vorbeugung und Behandlung von allergischer Rhinitis
UA27060C2 (uk) Спосіб стимулюваhhя зовhішhьої секреції підшлуhкової залози
BG100116A (bg) Инвазивен метод за лечение на енкопреза и енурезис ноктурна в комбинация или поотделно
IE900303L (en) 18-cyanoprogesterone derivatives

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0828492

Country of ref document: EP

EEIH Change in the person of patent owner